Drug intelligence / Profile preview

Citronac-KD

Development stage: Unknown
Lead developer: Meditrina Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Citronac-KD is a dietary supplement developed by Meditrina Pharmaceuticals for urological and nephrological support. It consists of a patented blend of citrates, including sodium citrate, providing the equivalent of 80mEq of bicarbonate per dose. The product is designed to enrich citrate intake and help maintain optimal blood pH (7.35-7.45) by correcting metabolic acidosis in patients with chronic kidney disease (CKD). By restoring acid-base balance, it aims to slow the decline of the glomerular filtration rate (GFR) and the overall progression of CKD. It is administered orally as a sachet dissolved in liquid.

Brand names: Citronac-KD

Targets

CIT (Citrate)

Beyond the preview

Go deeper on Citronac-KD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Citronac-KD.

Explore the full profile